Pfizer To Cut Drug Prices, Announces $70 Billion US Investment, And Discounted Sales Via Trumprx
Pfizer is expected to implement broad reductions in US drug prices, with Medicaid patients receiving“most favored nation” pricing on select medicines, the news outlet stated. This approach aligns with Trump's ongoing push to bring US drug costs in line with what foreign purchasers pay.
Direct-to-consumer discounts via TrumpRxThe company will also launch discounted direct-to-consumer sales through a planned government website called TrumpRx. This platform will allow Americans to pay cash for certain high-volume drugs at government-negotiated rates.
Investment in R&D and domestic manufacturingPfizer will announce a $70 billion investment in research, development, and domestic manufacturing, signaling a major expansion of its US operations.
White House support“President Trump is doing more to lower healthcare costs than anyone else in Washington, DC,” said White House spokesman Kush Desai.“While Democrats are threatening to shut down the government to subsidize health care for illegal aliens, President Trump is leveraging the power of the federal government to drastically cut drug prices for everyday Americans.”
Policy details and industry pushbackThe most-favored-nation pricing policy requires companies to reduce Medicaid prices, match US prices to those abroad for future drugs, and set up discounted direct-to-consumer sales.
Trump's initiative follows letters sent in July to 17 major drugmakers-including Eli Lilly, Novo Nordisk, and Pfizer-demanding compliance by September 29. The President warned he would“deploy every tool in our arsenal” against companies that failed to follow through.
Domestic production and tariffsIn addition to price reductions, Trump has pressed drugmakers to increase domestic production. He recently announced plans to impose 100% tariffs on imported branded or patented drugs unless manufacturers build US plants, with the levies set to begin October 1.
(With Bloomberg inputs)
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research

- Alt.Town Introduces $TOWN Token Utility Across Platform Services And Launches Valuefi Deposit Event
- BTCC Exchange Maintains 143% Total Reserve Ratio In September 2025 Demonstrating Continued Financial Strength
- Salvium Solves The Privacy Paradox: Salvium One Delivers Mica-Compliant Privacy That Exchanges Can List
- Zebu Live 2025 Welcomes Coinbase, Solana, And Other Leaders Together For UK's Biggest Web3 Summit
- Tapbit At TOKEN2049: Reshaping The Crypto Landscape Through Product Innovation
- Thrivestate Launches“Fly Before You Buy” Program, Enabling International Buyers To Explore Dubai Before Committing
Comments
No comment